Globalseo is still translating this page... (closing in 5s)
Skip to main content

TNF receptor superfamily member 1A

The TNFRSF1A gene provides instructions for making a protein called tumour necrosis factor receptor 1 (TNFR1). This protein is found spanning the membrane of cells, with part of the TNFR1 protein outside the cell and part of the protein inside the cell. Outside the cell, the TNFR1 protein attaches (binds) to another protein called tumour necrosis factor (TNF). The interaction of the TNF protein with the TNFR1 protein causes the TNFR1 protein to bind to two other TNFR1 proteins, forming a three-protein complex called a trimer. This trimer formation is necessary for the TNFR1 protein to be functional.

Normal function

The TNFRSF1A gene provides instructions for making a protein called tumour necrosis factor receptor 1 (TNFR1). This protein is found spanning the membrane of cells, with part of the TNFR1 protein outside the cell and part of the protein inside the cell. Outside the cell, the TNFR1 protein attaches (binds) to another protein called tumour necrosis factor (TNF). The interaction of the TNF protein with the TNFR1 protein causes the TNFR1 protein to bind to two other TNFR1 proteins, forming a three-protein complex called a trimer. This trimer formation is necessary for the TNFR1 protein to be functional.

The binding of the TNF and TNFR1 proteins causes the TNFR1 protein to send signals inside the cell. Signaling from the TNFR1 protein can trigger either inflammation or self-destruction of the cell (apoptosis). Signaling within the cell initiates a pathway that turns on a protein called nuclear factor kappa B, which triggers inflammation and leads to the production of immune system proteins called cytokines. Apoptosis is initiated when the TNFR1 protein, bound to the TNF protein, is brought into the cell and starts a process known as the caspase cascade.

Conditions referring to this gene or chromosome

Other names

p55

p55-R

TNF-R

TNF-R1

TNF-R55

TNFR-I

TNFR1

TNFR55

TNR1A_HUMAN

tumour necrosis factor binding protein 1

tumour necrosis factor receptor superfamily member 1A

tumour necrosis factor receptor superfamily, member 1A

tumour necrosis factor receptor type 1

tumour necrosis factor-alpha receptor

Related patient information and medicines

Hidradenitis suppurativa

Patient information leaflet

Hidradenitis suppurativa

Hidradenitis suppurativa is a long-term (chronic) skin condition that leads to painful and repeated lumps of pus (boils or abscesses). Hidradenitis suppurativa tends to run in families; about one-third of people with hidradenitis suppurative have a family member who is affected. The most promising of these treatments are monoclonal antibodies,.

Biological medicines for rheumatoid arthritis

Patient information leaflet

Biological medicines for rheumatoid arthritis

Biological medicines mimic substances produced by the human body, such as antibodies. For example, some of these biological medicines block a chemical called tumour necrosis factor alpha (TNF-alpha) which plays an important role in causing inflammation in the joints. Medicines that block TNF include adalimumab, certolizumab pegol, etanercept,.

Immunosuppression

Patient information leaflet

Immunosuppression

Mycophenolate mofetil. Monoclonal antibodies - of which there are many ending in "mab", such as bevacizumab, rituximab and trastuzumab. Anti-TNF drugs such as etanercept , infliximab, adalimumab, certolizumab and golimumab. (TNF stands for anti tumour necrosis factor, and some of the "mab" medicines above act against TNF, so there is some overlap.

Axial spondyloarthritis

Patient information leaflet

Axial spondyloarthritis

Axial spondyloarthritis (also known as axSpA or axi. Biological medicines Biologics can be used to control the disease process. The main ones used for axial spondyloarthritis are called tumour necrosis factor (TNF) inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab or infliximab). Other medicines, such as secukinumab, bimekizumab or.

Ankylosing spondylitis

Patient information leaflet

Ankylosing spondylitis

Ankylosing spondylitis is an auto-immune disease. In ankylosing spondylitis, a chemical called cytokine tumour necrosis factor alpha (TNF-alpha) is involved in causing inflammation. ...bitorsTNF-alpha inhibitors are also sometimes called anti-TNF-alpha drugs. In the UK the National Institute for Health and Care Excellence (NICE) recommends that.

Psoriatic arthritis

Patient information leaflet

Psoriatic arthritis

Some DMARDs also have a beneficial effect on reducing the rash of psoriasis. Newer disease-modifying medicines A new class of recently developed medicines modify the effect of TNF alpha. The chemical TNF alpha plays an important role in causing inflammation in joints and skin. Blocking the effect of TNF alpha has been shown to reduce damage to.

Article history

The information on this page is written and peer reviewed by qualified clinicians.
  • 18 Aug 2020 | Latest version
  • 1 Aug 2011 | Originally published

Join the conversation

Share your thoughts or experiences with others in our patient communities.

Disclaimer: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.
flu eligibility checker

Ask, share, connect.

Browse discussions, ask questions, and share experiences across hundreds of health topics.

Sign up to the Patient newsletter

Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.

Please enter a valid email address

By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.